Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma: Symptom burden and quality of life

S.A. Eikeland*, K.B. Smeland, F. Mols, U. Fagerli, S. Bersvendsen, C.E. Kiserud, A. Fossa

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Background
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin’s lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and determine associated factors, including impact on health-related quality of life (HRQoL).

Material and methods
A questionnaire, including EORTC QLQ-CIPN-20 for CIPN related symptoms and SF-36 for HRQoL, was completed by 303 HL survivors at a median of 16 years after diagnosis. CIPN results were compared to a normative population (n = 606). CIPN associated factors were identified by linear regression analysis.

Results
Total CIPN score and subscores were significantly higher in HL survivors compared to controls. In multivariate analysis of HL survivors, a number of comorbidities (p < 0.001) and female gender (p = 0.05) were significantly associated with more CIPN. No association with disease or treatment factors was found. In a multivariate analysis including survivors and controls, the number of comorbidities (p < 0.001) and caseness (p < 0.001) were significantly associated with more CIPN. In HL survivors higher CIPN score was associated with reduced HRQoL (p < 0.001).

Conclusion
HL survivors more than a decade after treatment report higher neuropathy-related symptom burden than controls, with a negative impact on HRQoL. Symptoms may be related to factors other than neurotoxic chemotherapy.
Original languageEnglish
Pages (from-to)911-920
JournalActa Oncologica
Volume60
Issue number7
DOIs
Publication statusPublished - 2021

Keywords

  • ASSOCIATION
  • Adverse effects
  • CANCER
  • COMORBIDITY
  • DISEASE
  • Hodgkin's lymphoma survivor
  • NEUROTOXICITY
  • POPULATION
  • QUESTIONNAIRE
  • STANDARD
  • SURVIVORS
  • VINCRISTINE
  • cancer survivorship
  • chemotherapy-induced peripheral neuropathy

Fingerprint

Dive into the research topics of 'Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma: Symptom burden and quality of life'. Together they form a unique fingerprint.

Cite this